An observational study in Pregnancy Related and Venous Thromboembolism, sponsored by University of Calgary. Recruiting at 14 sites in 5 countries. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by University of Calgary · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Venous Thromboembolism with a site in Canada — 13 open to participants now, 13 under way, 8 of them phase 3. Venous Thromboembolism · Canada.
Among the 118 studies in Venous Thromboembolism with a site in Canada, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2023, is one of 20 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 108th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →13 of the 118 studies in Venous Thromboembolism with a site in Canada are open now. Recruiting first, the newest first:
University of Calgary · Sites in Canada, Belgium, Denmark and 4 more countries
Ages 18+ · Women only
Regeneron Pharmaceuticals · Sites in Canada, United States
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 65+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 26 · Phase 3 51 · Phase 4 13
First in 1994; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 825 is above the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Median enrollment 506 across the 98 interventional studies, 605 across the 20 observational. Of the 100 that completed or were terminated, 34 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 118 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 5 studies filed under Venous Thromboembolism — fewer than ten, so there is no comparison to draw.
2 of the studies in Venous Thromboembolism with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 118 studies in Venous Thromboembolism with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.
The goal of this study is to provide quality data using standardized outcome definitions on postpartum bleeding events, venous thromboembolism (VTE) risk, delivery experience outcomes and health care utilization for intrapartum and postpartum anticoagulation management among pregnant individuals on low-molecular-weight heparin (LMWH) for prevention of treatment of VTE.
Pregnant individuals on anticoagulation for VTE-related indications
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of:
Exclusion Criteria:
Incidence of MB and CRNMB
To estimate the combined incidence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) for the six most common antepartum strategies.
Time frame: Delivery up to 6 weeks postpartum
Practice Patterns
To determine the practice patterns of intrapartum and postpartum anticoagulant management for pregnant individuals on LMWH for VTE indications across participating centres.
Time frame: Prior to delivery and following delivery
MB and CRNMB incidence in the immediate and 6 W postpartum period
To estimate the incidence of MB and CRNMB in the immediate postpartum period (within 24 hours) and up to 6 weeks postpartum for each antepartum strategy.
Time frame: Within 24 hours of delivery and up to 6 weeks postpartum
MB and CRNMB incidence up to 6 W postpartum related to anticoagulation resumption
To estimate the incidence of MB and CRNMB up to 6 weeks postpartum, based on the time and dose of postpartum anticoagulation resumption.
Time frame: 6 weeks postpartum
Incidence of VTE
To estimate the incidence of symptomatic objectively confirmed VTE up to 6 weeks postpartum for each antepartum strategy.
Time frame: Delivery to 6 weeks postpartum
Wound Hematoma
To estimate the incidence of wound hematoma complications up to 6 weeks postpartum for each antepartum strategy.
Time frame: Delivery to 6 weeks postpartum
Anti-Xa levels
To compare anti-Xa levels on admission for delivery in individuals with and without immediate postpartum MB and CRNMB.
Time frame: Delivery
Hemoglobin Levels around Delivery
To compare a change in hemoglobin levels before and after delivery in individuals with and without immediate postpartum MB and CRNMB.
Time frame: Before and after delivery
Patient Experience
To describe delivery experience outcomes including neuraxial anesthesia (eligible vs. preferred vs. actual), patient satisfaction, and patient choice relating to delivery management options.
Time frame: Delivery
Healthcare Utilization
To quantify healthcare utilization including hospital length of stay, postpartum length of stay, repeat procedures and induction of labor resource utilization.
Time frame: Before and after delivery
Plan to share: Yes — Please contact study PI for requests.
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Jun 2029, 74 months after the start.
Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 74 months is above that.
Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.